How did LXEO's operating expenses trend in Q4 2024?

Lexeo Therapeutics' operating expenses for Q4 2024 are not currently available. However, the company's financial results for Q3 2024 provide insights into its spending trends.

1. **Overall Financial Performance**: Lexeo Therapeutics reported a net loss of $29.49 million for Q3 2024, compared to $20.11 million in the same period in 2023. This increase in net loss reflects higher operating expenses.
2. **Operating Expenses**: The company's total operating expenses for Q3 2024 were $31.5 million, an increase of $11.3 million compared to the same period in 2023. This indicates a trend of rising operating expenses.
3. **Comparison with Previous Quarters**: Lexeo Therapeutics' operating expenses have been on an upward trend. For the nine months ended September 30, 2024, total operating expenses were $78.4 million, up by $24.8 million from the previous year. This suggests that the company's spending has been increasing over time.
4. **Investment in Clinical Trials and Regulatory Activities**: The company's increased spending can be attributed to its ongoing clinical trials and regulatory activities. Lexeo has made significant progress in its clinical and preclinical programs, including the completion of enrollment in the LX2006 SUNRISE-FA Phase 1/2 trial and the LX2020 HEROIC-PKP2 Phase 1/2 trial. These developments require substantial investment in research and development.

In conclusion, Lexeo Therapeutics' operating expenses for Q4 2024 are not available, but the trend of increasing expenses is evident from the company's financial results for Q3 2024. The company's investment in clinical trials and regulatory activities is a key factor driving this trend.